Important Role of a Putative Lytic Transglycosylase Cj0843c in β-Lactam Resistance in Campylobacter jejuni by Ximin Zeng et al.
ORIGINAL RESEARCH
published: 17 November 2015
doi: 10.3389/fmicb.2015.01292
Edited by:
Gilberto Igrejas,
University of Trás-os-Montes and Alto
Douro, Portugal
Reviewed by:
Elaine Allan,
University College London, UK
Alessandra Polissi,
Università degli Studi di
Milano-Bicocca, Italy
*Correspondence:
Jun Lin
jlin6@utk.edu
Specialty section:
This article was submitted to
Antimicrobials, Resistance
and Chemotherapy,
a section of the journal
Frontiers in Microbiology
Received: 20 July 2015
Accepted: 04 November 2015
Published: 17 November 2015
Citation:
Zeng X, Gillespie B and Lin J (2015)
Important Role of a Putative Lytic
Transglycosylase Cj0843c
in β-Lactam Resistance
in Campylobacter jejuni.
Front. Microbiol. 6:1292.
doi: 10.3389/fmicb.2015.01292
Important Role of a Putative Lytic
Transglycosylase Cj0843c in
β-Lactam Resistance in
Campylobacter jejuni
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Department of Animal Science, The University of Tennessee, Knoxville, TN, USA
Beta-lactam antibiotics are an important class of antibiotics for treating bacterial
infections. Despite prevalent β-lactam resistance in Campylobacter jejuni, the leading
bacterial cause of human diarrhea in developed countries, molecular mechanism of
β-lactam resistance in C. jejuni is still largely unknown. In this study, C. jejuni 81–176
was used for random transposon mutagenesis. Screening of a 2,800-mutant library
identified 22 mutants with increased susceptibility to ampicillin. Of these mutants, two
mutants contains mutations in Cj0843c (a putative lytic transglycosylase gene) and in
its upstream gene Cj0844c, respectively. Complementation experiment demonstrated
that the Cj0843 contributes to β-lactam resistance. The Cj0843c insertional mutation
was subsequently introduced to diverse C. jejuni clinical strains for MIC test, showing
that Cj0843c contributes to both intrinsic and acquired β-lactam resistance of
C. jejuni. Consistent with this finding, inactivation of Cj0843c also dramatically reduced
β-lactamase activity. Genomic examination and PCR analysis showed Cj0843c is widely
distributed in C. jejuni. High purity recombinant Cj0843c was produced for generation
of specific antiserum. The Cj0843 was localized in the periplasm, as demonstrated by
immunoblotting using specific antibodies. Turbidimetric assay further demonstrated the
capability of the purified Cj0843c to hydrolyze cell walls. Inactivation of Cj0843c also
significantly reduced C. jejuni colonization in the intestine. Together, this study identifies
a mechanism of β-lactam resistance in C. jejuni and provides insights into the role of cell
wall metabolism in regulating β-lactamase activity.
Keywords: beta-lactamase, peptidoglycan, random transposon mutagenesis, lytic transglycosylase
INTRODUCTION
Beta-lactam antibiotics, which inhibit biosynthesis of bacterial cell wall, are the most commercially
available antibiotics in the market. For instance, in 2009, beta-lactam antibiotics account for more
than half of the total antibiotic sales globally (Hamad, 2010). However, the eﬃcacy of the β-lactam
based therapy is severely threatened by a variety of β-lactam resistance mechanisms in bacteria,
such as production of beta-lactamases (Korfmann and Wiedemann, 1988; Iaconis and Sanders,
1990; Jacoby, 2009), expression of the penicillin-binding proteins (PBPs) with reduced aﬃnity
for β-lactam antibiotics (Fuda et al., 2004), and extrusion of β-lactam using multi-drug eﬄux
pumps (Nikaido, 1998; Vila and Martinez, 2008). Production of β-lactamase has been a major and
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threatening β-lactam resistance mechanism. Recently, increasing
evidence demonstrate a direct link between cell wall metabolism
and regulation of β-lactamase activity in Gram-negative bacteria,
which provides insights into the development of innovative
strategies to counteract β-lactam resistance in pathogenic
bacteria (Zeng and Lin, 2013).
Campylobacter jejuni is the leading bacterial cause of human
gastroenteritis in the developed countries (Humphrey et al.,
2007). Clinical symptoms include fever and watery diarrhea
in humans. In rare case, campylobacteriosis can cause severe
sequelae such as Guillain–Barré syndrome, an acute ﬂaccid
paralysis that may lead to respiratory muscle compromise
and death (Nachamkin et al., 1998; Hughes and Cornblath,
2005; Nyati and Nyati, 2013). The annual incidence of
campylobacteriosis in the United States is approximately 1%
(Poly and Guerry, 2008), resulting in 1.7 billion dollars cost in
medical practice and productivity (Hoﬀmann et al., 2012). In
parallel to its increased prevalence, Campylobacter is increasingly
resistant to macrolides and ﬂuoroquinolones, the two major
clinical antibiotics (Luo et al., 2005; Caldwell et al., 2008;
Koningstein et al., 2011). Recently, it has been proposed that an
oral β-lactam, such as co-amoxiclav, may provide an alternative
therapy for Campylobacter infection (Elviss et al., 2009; Griggs
et al., 2009). However, β-lactam resistant C. jejuni strains have
also been observed in epidemiological studies (Lachance et al.,
1991; Griggs et al., 2009). Thus, understanding the mechanisms
of β-lactam resistance in C. jejuni would help us develop eﬀective
therapeutic strategy that will allow the use of existing β-lactams
against resistant C. jejuni. In Campylobacter, two beta-lactam
resistance mechanisms have been characterized, which include
the presence of CmeABC multi-drug eﬄux pump (Lin et al.,
2002) and the production β-lactamase OXA-61 (Alfredson and
Korolik, 2005; Griggs et al., 2009). Despite these progresses,
the ﬁndings from recent studies strongly suggest the existence
of novel β-lactamases and/or regulatory system in C. jejuni for
β-lactam resistance (Griggs et al., 2009; Zeng et al., 2014).
In this study, using random mutagenesis, we identiﬁed a
putative lytic transglycosylase (LT) Cj0843c that is required
for intrinsic and acquired β-lactam resistance in C. jejuni.
This ﬁnding was further validated by a series of molecular,
biochemical and genomic examination. Consistent with this
ﬁnding, inactivation of Cj0843c, which is highly conserved in
C. jejuni, dramatically reduced β-lactamase activity. The role of
Cj0843c in peptidoglycan metabolism was validated by a standard
LT assay using puriﬁed Cj0843c. This study provides compelling
evidence that Cj0843c, a putative LT, plays a critical role in
regulating β-lactamase-mediated β-lactam resistance in C. jejuni.
MATERIALS AND METHODS
Bacterial Strains, Plasmids, and Culture
Conditions
The major bacterial strains and plasmids used in this study
are listed in Table 1. The C. jejuni strains were grown
routinely in Müller-Hinton (MH) broth or agar at 42◦C in
tri-gas incubator (85% N2, 10% CO2, 5% O2). Escherichia
TABLE 1 | Key bacterial plasmids and strains used in this study.
Plasmids or strains Description Source or
reference
Plasmids
pRY111 Escherichia coli–Campylobacter
shuttle vector, kanamycin resistant
Yao et al., 1993
pCj843c pRY111 derivative containing
Cj0843c, Cj0844c, and Cj0845c
This study
pCj844c pRY111 derivative containing
Cj0843c and Cj0844c
This study
pET28b-Cj0843c Expression vector for recombinant
Cj0843c, Kanr
Novagen
Strains
Campylobacter jejuni
JL241 NCTC 11168, human isolate Parkhill et al., 2000
JL890 JL241 derivative with transposon
inserted into Cj0843c, Kanr
This study
JL990 JL890 derivative, complemented
with pCj843c
This study
JL28 81–176, human isolate, for random
transposon mutagenesis
Black et al., 1988
JL30 81–176 (JL28) derivative with
transposon inserted into cmeB
gene, Kanr
Lin et al., 2002
JL916 JL28 derivative with EZ::TN
<KAN-2> transposon inserted into
Cj0843c, Kanr
This study
JL926 JL916 derivative, complemented
with pCj843c
This study
JL962 81–176 derivative, ampicillin
resistant. The β-lactamase gene
blaOXA−61 was introduced into
chromosome via natural
transformation using genomic DNA
from ampicillin resistant C. jejuni
21190 (Zeng et al., 2014)
This study
JL963 JL962 derivative. The Cj0843c::kan
mutation was introduced into
chromosome via natural
transformation using genomic DNA
from JL916, Kanr
This study
JL995 81–176 (JL28) derivative, Kanr. The
pgp1::kan mutation was introduced
into JL28 chromosome via natural
transformation using genomic DNA
of the pgp1 mutant (Frirdich et al.,
2012)
This study
JL996 JL962 derivative. The pgp1::kan
mutation was introduced into
JL962 chromosome via natural
transformation using genomic DNA
of the pgp1 mutant (Frirdich et al.,
2012)
This study
E. coli
DH5α F- 80lacZM15
(lacZYA-argF )U169 recA1 endA1
hsdR17 (rk−, mk+) phoA supE44
thi-1 gyrA96 relA1 λ-
Invitrogen
JL985 pET28b-Cj0843c in BL21(DE3) This study
coli strains were grown routinely in Luria-Bertani (LB) broth
with shaking (250 rpm) or on agar at 37◦C overnight. When
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needed, culture media were supplemented with ampicillin
(100 μg/ml), kanamycin (50 μg/ml), and chloramphenicol (Cm;
20 μg/ml).
Random Transposon Mutagenesis
We have successfully used C. jejuni 81–176 as a host strain for
in vivo random transposon mutagenesis using EZ-Tn5 < KAN-
2 > Tnp Transposome system (Epicentre; Lin et al., 2009; Hoang
et al., 2011, 2012; Zeng et al., 2013b). In this study, the wild-type
C. jejuni 81–176 (ampicillin Minimum inhibitory concentration
(MIC) = 1 μg/ml) was subjected to in vivo random transposon
mutagenesis; the procedure and screening strategy are detailed in
previous publications (Lin et al., 2009; Hoang et al., 2011, 2012;
Zeng et al., 2013b). Themutants with growth defects inMHbroth
containing kanamycin (50 μg/ml) and ampicillin (0.25 μg/mL)
were identiﬁed. To determine transposon insertion site, genomic
DNA extracted from the selected mutant was subjected to direct
sequencing as described previously (Lin et al., 2009; Hoang et al.,
2011; Zeng et al., 2013b).
Antimicrobial Susceptibility Test
The susceptibilities of C. jejuni strains to diﬀerent antimicrobials
(Fisher Bioreagents) were determined by a standard microtiter
broth dilution method with an inoculum of 106 CFU/ml as
described previously (Lin et al., 2002; Zeng et al., 2014). MIC for
speciﬁc antimicrobial was deﬁned by the lowest concentration
of the antimicrobial showing complete inhibition of bacterial
growth after 2 days of incubation at 42◦C under microaerophilic
condition.
Beta-lactamase Activity Assay
To measure β-lactamase activity in C. jejuni strains, standard
assay was performed on cell lysates of diﬀerent strains by
following previous procedure (Griggs et al., 2009; Zeng et al.,
2014) with minor modiﬁcations. Brieﬂy, late-log phase bacterial
cells were harvested from MH plates, washed with PBS, and
adjusted to an optical density at 600 nm of approximately 1.2
in PBS. Bacterial suspensions were sonicated and centrifuged
at 13,000 rpm for 5 min. The supernatant was subjected to
protein concentration measurement using BCA Protein Assay
kit (Pierce). One hundred microliter of supernatant containing
40 μg of protein was mixed with 0.8 ml of ice-chilled reaction
buﬀer (0.1 M phosphate; 1 mM EDTA, pH 7.0). Then 100 μl
of nitroceﬁn (500 μg/ml) was added to the above reaction
mix followed by incubation at 37◦C for 30 min. The activity
was determined by spectrometric at 486 nm. The molar
extinction coeﬃcient of hydrolyzed nitroceﬁn at 486 nm is
20,500 M−1 cm−1. The lysate from C. jejuni 81–176 was used
as negative control. The β-lactamase activity was expressed as
hydrolyzed nitroceﬁn (μM) per hr per mg of protein.
Complementation of C. jejuni 81–176
Transposon Mutants
The long fragment (containing the genes Cj0843c, Cj0844c, and
Cj0845c) and the short fragment (containing the genes Cj0844c
and Cj0845c) were PCR ampliﬁed from C. jejuni 81–176 using
primer pairs of Cj0843c_F/Cj0843c_R and Cj0843c_F/Cj0844c_R
(Table 2), respectively, with PfuUltra fusion II DNA polymerase
(Stratagene). The resulting fragments were ligated into SmaI-
digested shuttle vector pRY111 (Yao et al., 1993) and ligation mix
was introduced into E. coli DH5α by heat shock transformation.
The E. coli transformants containing the plasmid that bears the
three-gene (named pCj843c) or the two-gene fragment (named
pCj0844c) were identiﬁed and conﬁrmed by sequencing. Both
constructs were mobilized into C. jejuni 81–176 transposon
mutants by triparental conjugation as described previously (Zeng
et al., 2013a, 2014).
Natural Transformation
Natural transformation (biphasic method) was performed
following standard procedure as described by Wang and Taylor
(1990). Approximately 4 μg of C. jejuni genomic DNA was used
for natural transformation. The insertional Cj0843c mutations
in diﬀerent strains were conﬁrmed by PCR using primer pair
Cj0843c_F1 and Cj0843c_R1 (Table 2).
Production of Recombinant Cj0843c and
Generation of Polyclonal Antiserum
N-terminal histidine-tagged recombinant Cj0843c was produced
in E. coli by using pET-28b(+) vector. Brieﬂy, approximately
1568-bp fragment of Cj0843c was PCR ampliﬁed from C. jejuni
NCTC 81–176 using primer pairs rCj0843c_F1(NdeI) and
rCj0843c-pET28b_R(SalI; Table 2). The ampliﬁed product and
the vector pET-28b(+) were both digested with NdeI and
SalI and ligated with each other. Cloning, expression, and
puriﬁcation of rCj0843c were performed using the procedures
described in our previous publication (Lin et al., 2005; Zeng
et al., 2013a). The plasmid pET28b-Cj0843c in the E. coli
BL21(DE3) clone (JL985) producing rCj0843c was sequenced
to conﬁrm the correct insertion. The fractions containing pure
rCj0843c were pooled and dialyzed against 1 x PBS buﬀer
(Fisher Bioreagents). The concentration of the puriﬁed rCj0843c
was determined using BCA Protein Assay Kit (PierceTM).
Approximately 4 mg of highly puriﬁed rCj0843c was used
for the production of rabbit polyclonal antisera by Paciﬁc
Immunology Corp (Ramona, CA). Pre- and post-immune
serum samples were analyzed by immunoblotting against
pure rCj0843c to conﬁrm the generation of speciﬁc Cj0843c
antibody.
Enzymatic Activity of rCj0843c
The LT activity of rCj0843c was evaluated using turbidimetric
assay as reported before with minor modiﬁcation (Caldentey
and Bamford, 1992). In brief, the isogenic Cj0843c
mutant of C. jejuni 81–176 was harvested from three
overnight-cultured MH agar plates and resuspended in
50 ml Tris-HCl buﬀer (50 mM, pH 7.5). Then 3 ml of
chloroform was added in the suspension, which was kept
at room temperature for 30 min with gently shaking.
Subsequently, the chloroform-extracted cells (the crude cell
walls) were pelleted by centrifugation at 13,000 rpm for
5 min, washed once with 50 mM Tris-HCl buﬀer (pH7.5),
Frontiers in Microbiology | www.frontiersin.org 3 November 2015 | Volume 6 | Article 1292
Zeng et al. Regulation of Beta-Lactamase Activity
and resuspended in 50 ml of 50 mM Tris-HCl buﬀer
(pH 7.5).
To perform turbidimetric assay, the crude cell walls were
adjusted to ﬁnal OD450 nm of approximately 0.45 using 50 mM
Tris-HCl buﬀer. Then the puriﬁed rCj0843c was added to
1 ml of such cell wall suspension with ﬁnal concentration
of 24 μg/ml; the cell wall suspension containing PBS instead
of rCj0843c served as control. The decrease in turbidity at
450 nm was determined after 2.5 h of incubation at 37◦C.
The turbidimetric assay was performed with triplicate and
the statistical analysis of a Student’s t test was carried out
using SAS (v9.4). A P-value less than 0.05 was considered
signiﬁcant.
Localization of the Cj0843c
To determine cellular localization of Cj0843c, the periplasmic
and spheroplastic fractions were prepared using the PeriPrepsTM
Periplasting Kit (Epicentre) as detailed in our recent publication
(Zeng et al., 2013a). Diﬀerent cellular fractions were subsequently
subjected to SDS-PAGE and immunoblotting analysis as
described in our previous publications (Lin et al., 2002;
Zeng et al., 2009, 2013a). Brieﬂy, the protein samples were
separated by SDS-PAGE with a 12% (wt/vol) polyacrylamide
separating gel. After SDS-PAGE, proteins in the gels were
then electrophoretically transferred to nitrocellulose membranes
(Bio-Rad) at 60 V for 1 h at 4◦C. The membranes were
incubated with blocking buﬀer (5% Nestle skim milk powder
in PBS) for 16 h at 4◦C prior to incubation with primary
antibodies (Rabbit anti-Cj0843c at 1:5000 dilution in the blocking
buﬀer). To ensure the quality of periplasmic and spheroplastic
fractions, antibodies directed against CmeR (cytoplasmic control,
1:2000 dilution) were also used as primary antibodies. After
incubation at 25◦C for 1 h, the blots were washed three
times with PBS containing 0.05% Tween 20 and subsequently
incubated with secondary antibodies (1:50,000 dilution of
goat anti-rabbit IgG-HRP; Kirkegaard and Perry) at 25◦C
for 1 h. After washing, the blots were developed with the
SuperSignal West Dura Chemiluminescent Substrate (Thermo
Scientiﬁc). Prestained molecular weight markers (Bio-Rad) were
coelectrophoresed and blotted to allow estimation of the sizes of
the proteins.
Prevalence of Cj0843c in C. jejuni
Total 30 C. jejuni strains from diﬀerent hosts and geographically
diverse areas were grown microaerophilically to late exponential
phase and harvested by centrifugation. The cell pellets were
suspended in 100 μL of water and lysed by boiling for 5 min.
After centrifugation, the supernatants were used as template in
PCR assay with highly Cj0843c-speciﬁc primers Cj0843c_F1 and
Cj0843c_R1 (Table 2). For bioinformatic analysis of Cj0843c
prevalence among available genome sequences, total 103 C. jejuni
genomes were extracted from Integrated Microbial Genomes1
and the multi-sequence alignment was analyzed using Clustal
Omega2. In addition, presence of Cj0843c homolog was also
examined in the genomes of 49 Campylobacter coli and 298
Helicobacter pylori strains.
Chicken Colonization Experiment
Campylobacter jejuni 81–176 wild-type strain together with
its isogenic Cj0843c mutant (JL916) and the complementation
strain (JL926; Table 2) were used for colonization assay in a
chicken model system as described in previous studies (Lin et al.,
2002; Lin and Martinez, 2006; Hoang et al., 2011; Zeng et al.,
2013a). The chicken study was approved by the Institutional
Animal Care and Use Committee at The University of Tennessee
(Protocol 1387 under oversight of the IACUC Chair Carla
Sommardahl). Brieﬂy, 1-day-old broiler chickens were obtained
from a commercial hatchery (Hubbard Hatchery, Pikesville,
TN, USA). The chickens were negative for Campylobacter as
determined by culturing cloacal swabs prior to use in this study.
Three groups of 4-days-old chickens (10 birds/group) were
inoculated with diﬀerent bacteria via oral gavage using a dose
approximately 105 CFU of fresh late log-phase C. jejuni per bird.
Notably, the motility of parent strain and its Cj0843c mutant
was conﬁrmed to be at a comparable level prior to challenge.
The isogenic Cj0843c mutant displayed reduced growth in MH
broth when compared to its parent strain. However, the fresh
C. jejuni cultures with similar growth phase, reﬂected by the
ﬁnal OD600 nm measurement, were used to challenge chickens;
the bacteria in such cultures were assumed to be in the same
1https://img.jgi.doe.gov/cgi-bin/imgm_hmp/main.cgi
2http://www.ebi.ac.uk/Tools/msa/clustalo/
TABLE 2 | Major primers used in this study.
Primer DNA Sequence (5′–3′)a Product size (bp) Target gene and function
Cj0843c_F AACAAAATCCCAAGCTAAAGTCA 3,767 Cj0843c, Cj0844c and Cj0845c
operon
Cj0843c _R TTCTAGACAAGACAAGTAAAGATGATG
Cj0844c_R CAAGTGAATTTTCTTCCTTTTTGAG 2,028 With Cj0843c_F, to amplify Cj0844c
and Cj0845c
Cj0843c_F1 GCTCAAACCTTTAAAAATCAAAGA 586 Cj0843c prevalence and validation
of Cj0843c mutation
Cj0843c_R1 TTTGCCAAGCAAAAGGATCT
rCj0843c_F1(NdeI) GGAATTCCATATGCAATATAGTATAGAAAAACTCAAAAAGGAA 1,568 Recombinant Cj0843c
rCj0843c-pET28b_R(SalI) GCGCATGTCGACCTAAGATTTGTTTAGATCATTTGCC
aRestriction sites are underlined in the primer sequence and the names are identified in parentheses.
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physiological state. For each group, 5 birds were euthanized and
cecal samples were collected at 6 and 10 days post-inoculation.
The cecal contents from each bird were weighed and diluted in
MH broth. The diluted samples were plated onto MH agar plates
with Campylobacter speciﬁc selective supplements (Oxoid, UK).
The number of CFU per gram of cecal contents was calculated
for each chicken and was used as an indicator of the colonization
level. The detection limit of the plating methods was 102
CFU/g of cecal contents. A bird from which no Campylobacter
colonies were detected was assigned a conservative value of
99 CFU/g of cecal contents for the purpose of calculating
means and for statistical analysis. One-way analysis of variance
(ANOVA) followed by a least-signiﬁcant diﬀerence test was
used to analyze the signiﬁcant diﬀerences in colonization level
(log transformed). A P-value less than 0.05 was considered
signiﬁcant.
RESULTS
Cj0843c, a Putative Lytic
Transglycosylase, is Required for
Ampicillin Resistance
The C. jejuni 81–176 strain was used as a host strain to
generate a library consisting of 2,800 Tn5-insertional mutants.
Individual mutant grown in microtiter plates was replicated
into screening plates containing MH broth with sublethal
concentration of ampicillin (0.25 μg/ml). A total of 22
mutants displayed increased susceptibility to ampicillin. The
insertional sites of these mutants were mapped by direct
sequencing. It’s not surprising that most of them (20 mutants)
contains transposon insertion in cmeABC locus which encodes
CmeABC multidrug eﬄux pump system which was previously
shown to be involved in ampicillin resistance (Lin et al.,
2002, 2003). Speciﬁcally, transposon insertional mutations were
identiﬁed in cmeA (two diﬀerent sites with four mutants),
cmeB (two diﬀerent sites with four mutants), and cmeC (2
diﬀerent sites with 12 mutants). Interestingly, the other two
mutants have transposon insertion identiﬁed in two adjacent
genes, the CJJ81176_0859 and CJJ81176_0860 (hereinafter,
the corresponding universal locus names in C. jejuni NCTC
11168, Cj0843c and Cj0844c, were used). The Cj0843c was
annotated as a putative secreted LT. Speciﬁcally, Cj0843c
contains a highly conserved domain (COG0741, E-value is
3.53e-27) represented by MltE, an endo-speciﬁc LT from
E. coli that catalyzes hydrolysis of glycan chains to generate
short chains with 1,6-anhydro-MurNAc ends (Fibriansah et al.,
2012). Cj0844c was annotated as putative integral membrane
protein. Both mutants displayed fourfold MIC reduction for
ampicillin when compared to that of wild type 81–176
(Table 3).
Genome analysis showed that the start codon of Cj0843c
overlapped the stop codon of Cj0844c by 4 bp nucleotides. In
addition, there is only 2 bp nucleotide gap between the start
codon of Cj0844c and the stop codon of its upstream gene
Cj0845c. Therefore, the Cj0845c, Cj0844c, and Cj0843c may form
an operon. The transposon insertion into Cj0844c may cause
polar eﬀect, aﬀecting the expression of downstream geneCj0843c.
To test this, two constructs with diﬀerent length (pCj0843c and
pCj0844c) was constructed for complementation (Table 1). The
pCj0843c covers the whole three-gene operon while pCj0844c
only contains two upstream genes Cj0845c and Cj0844c. As
shown in Table 3, complementation with pCj0843c restored the
MIC of both mutants to the level of wild type strain. However,
complementation of the Cj0844c mutant with pCj0844c failed
to restore MIC of ampicillin to wild-type level, indicating that
the Cj0843c, not Cj0844c, is involved in ampicillin resistance in
C. jejuni 81–176.
To examine the role of Cj0843c in ampicillin resistance
in diﬀerent strains, the Cj0843c transposon mutation was
also introduced into C. jejuni NCTC 11168 via natural
transformation. As shown in Table 3, the isogenic Cj0843c
mutant of NCTC 11168 also displayed increased susceptibility
to ampicillin (eightfold reduction) while the MIC of the
complementation strain was the same as that of wild type strain.
Cj0843c is Involved in the Resistance to
Various β-lactam Antibiotics in
Campylobacter
We also examined if inactivation of Cj0843c aﬀected
susceptibilities of C. jejuni to diﬀerent β-lactam antibiotics. As
shown in Table 4, susceptibilities of Cj0843c mutant to various
β-lactam antibiotics (penicillin G, ticarcillin, carbenicillin, and
cloxacillin) signiﬁcantly increased (fourfold) when compared
to wild-type 81–176 strain. Complementation of the isogenic
Cj0843cmutant with pCj0843c restoredMIC of ampicillin to wild
type level (Table 4). In terms of other types of antimicrobials,
such as bile salts (cholic acid and deoxycholic acid), ciproﬂoxacin
and ethidium bromide (Table 4), the susceptibilities of Cj0843c
mutant did not change when compared to wild-type strain.
Cj0843c also Plays an Important Role in
Acquired Ampicillin Resistance
Although C. jejuni 81–176 lacks beta-lactamase gene blaOXA−61
in the genome (Griggs et al., 2009), it could acquire high-
level ampicillin resistance (Ampr) due to the acquisition of
active beta-lactamase blaOXA−61 from C. jejuni 21190 via natural
transformation (Zeng et al., 2014). The MIC of ampicillin for
the Ampr derivative of 81–176 was 128 μg/mL, which is 128-
fold higher than the MIC of wild-type 81–176 (Figure 1), as
reﬂected by the dramatic change of the beta-lactamase activity
(Figure 1). However, inactivation of Cj0843c in the Ampr
derivative of 81–176 dramatically reduced MIC (8 μg/mL) as
well as the beta-lactamase activity in cell lysates (Figure 1). In
contrast, although mutation in multidrug eﬄux pump gene cmeB
(Lin et al., 2002) in the Ampr derivative led to reduced MIC
of ampicillin (16 μg/mL), the beta-lactamase activity was not
changed (Figure 1). This ﬁnding clearly indicated that Cj0843c
also plays an important role in β-lactamase-mediated ampicillin
resistance bymodulating the activity of β-lactamase BlaOXA−61 in
C. jejuni.
Frontiers in Microbiology | www.frontiersin.org 5 November 2015 | Volume 6 | Article 1292
Zeng et al. Regulation of Beta-Lactamase Activity
TABLE 3 | Susceptibilities of two representative C. jejuni strains and their isogenic mutants to ampicillin.
Parent strain MIC (μg/mL)
Wild type Cj0843c− Cj0844c− Cj0843c−/pCj0843c Cj0844c−/pCj0843c Cj0844c−/pCj0844c CmeB−
81–176 1 0.25 0.25 1 1 0.25 0.0625
NCTC 11168 16 2 NDa 16 ND ND 4
a ND, not determined.
TABLE 4 | Cj0843 is only involved in C. jejuni resistance to various
β-lactams.
Chemical 81–176 WT cj0843c::Tn5 cj0843c::Tn5/pCj0843c
Penicillin G (μg/ml) 16 4 16
Ticarcillin (μg/ml) 256 64 256
Carbenicillin (μg/ml) 64 16 64
Cloxacillin (μg/ml) 512 128 512
Cholic acid (mg/ml) 12.5 12.5 N/Da
Ciprofloxacin (μg/ml) 0.25 0.25 N/D
Deoxycholic acid (mg/ml) 20 20 N/D
Ethidium bromide (μg/ml) 1 1 N/D
aN/D, not determined.
To determine the role of Pgp1, an identiﬁed gene involved
cell wall metabolism in C. jejuni (Frirdich et al., 2012), in
ampicillin resistance, the pgp1::kan mutation was introduced
into the wild-type 81–176 and its Ampr derivative in this
study via natural transformation using genomic DNA of the
pgp1 mutant, creating isogenic pgp1 mutant JL995 and JL996,
respectively (Table 1). The MICs for JL995 and JL996 are 1 and
128 μg/mL, respectively, which are the same as those for their
corresponding parent strains. Consistent with this ﬁnding, the
beta-lactamase activity was not changed due to the inactivation
of pgp1.
The Prevalent and Highly Conserved
Cj0843c is Required for Ampicillin
Resistance in Diverse C. jejuni Isolates
It’s well known that the genome of C. jejuni species displayed
considerable plasticity (de Boer et al., 2002; Poly et al., 2008;
Duong and Konkel, 2009). In this study, a PCR survey was
performed, demonstrating that the Cj0843c was present in 30
diverse C. jejuni isolates (data not shown). The representative
isolates were listed in Table 5. Regardless of the level of
β-lactamase activity and the level of ampicillin resistance,
introduction of Cj0843c mutation into these isolates all resulted
in the decrease of MIC of ampicillin by more than fourfold
(Table 5).
In addition to this PCR survey, genome analysis also provided
compelling evidence showing Cj0843c was highly conserved in
C. jejuni and other closely related species. Speciﬁcally, Cj0843c
was present in all 101 currently available C. jejuni genomes
deposited in the database. Notably, the three-gene operon
containing Cj0843c is also highly conserved in the genomes of
diﬀerent ε-proteobacteria, including 101 C. jejuni, 49 C. coli,
FIGURE 1 | Effect of Cj0843c mutation on intracellular β-lactamase
activities and ampicillin resistance in Campylobacter jejuni. The
ampicillin MIC values were listed below each corresponding strain. Ampr, the
81–176 derivative with β-lactamase gene blaOXA−61 introduced into
chromosome via natural transformation using genomic DNA from ampicillin
resistant C. jejuni 21190 (Zeng et al., 2014). The procedure for
nitrocefin-based β-lactamase activity assay was detailed in Materials and
Methods. The activity was determined by spectrometric change at 486 nm.
The molar extinction coefficient of hydrolyzed nitrocefin at 486 nm is
20,500 M−1 cm−1. The β-lactamase activity was expressed as hydrolyzed
nitrocefin (μM) per hr per mg of protein.
and 298 H. pylori (Supplementary Figure S1 and detailed in
Supplementary Table S1).
The multi-sequence alignment data show the percentage aa
identity among C. jejuni strains ranges from 93 to 100%. The
across-species alignment shows that the aa identity and homology
between C. jejuni NCTC 11168 and C. coli RM2228 are 79 and
89%, respectively, and those between C. jejuni NCTC 11168 and
H. pylori 26695 are 31 and 51%, respectively.
The Cj0843c is Localized in Periplasm
Based on annotation, Cj0843c is predicted to interact with the
glycan strand of the periplasmic peptidoglycan. To conﬁrm
this, we ﬁrst cloned Cj0843c into expression vector pET-28b
and produced N-terminal 6xHis tagged recombinant Cj0843c
(rCj0843c). Majority of rCj0843c is in the soluble fraction
and was successfully puriﬁed by Ni-NTA aﬃnity column
(Figure 2A).
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TABLE 5 | Cj0843c is prevalent and involved in intrinsic and acquired ampicillin resistance in different clinical C. jejuni isolates.
Strain Source/host Cj0843ca β-Lactamase activityb MIC (μg/ml)
Wild type Cj0843c::Tn5
JL241 Human + − 16 4
JL36 Chicken + ± 8 1
JL78 Human + − 4 0.25
JL81 Human + − 4 0.5
JL85 Human + − 2 0.25
JL90 Human + − 2 0.5
JL95 Ovine + + 16 2
JL100 Human + + 16 0.5
JL115 Human + ++++ 256 16
49 Chicken + − 4 0.25
Cj41 Chicken + ± 8 1
SO40 Bovine + − 16 1
JL98 Human + + 8 2
86 Chicken + − 16 2
aThe prevalence of Cj0843c is detected by PCR using primer Cj0843c_F1 and Cj0843c_R1.
bThe β-lactamase activity of each clinical isolate was measured using the cell lysate with the nitrocefin assay (Griggs et al., 2009). A yellow to red color change within
5 min at 37◦C indicated a β-lactamase-positive reaction. +, positive β-lactamase activity; −, negative β-lactamase activity; ±, weak β-lactamase activity; ++++, red
color developed immediately upon addition of substrate nitrocefin.
The speciﬁc Cj0843c antiserum was successfully raised and
was used for immunoblotting to determine localization of
Cj0843c in C. jejuni. As shown in Figure 2B, Cj0843c is
detected in the periplasm fraction but not in the spheroplast
fraction of wild-type cells (left panel). The Cj0843c was not
detected in the periplasm fraction of the isogenic Cj0843c
mutant either (left panel in Figure 2B). As a control, CmeR,
an intracellular regulator, is only detected in the spheroplast
fractions in both wild type and Cj0843c mutants (right
panel in Figure 2B). This immunoblotting analysis provides
compelling evidence that that Cj0843c is localized in the
periplasm, the place where peptidoglycan resides in Gram-
negative bacteria.
Lytic Transglycosylase Activity of
rCj0843c
The chloroform-treated Cj0843cmutant cells was used as cell wall
substrates because the rCj0843c action sites on cell walls from this
mutant are possibly intact. As shown in Figure 2C, the decrease
in OD450nm (OD450nm) in the reaction solution containing the
rCj0843c is signiﬁcantly larger than PBS control (P < 0.05),
indicating the capability of rCj0843c as LT to hydrolyze cell
wall.
Cj0843c is Required for C. jejuni
Colonization
The role of Cj0843c in in vivo survival of C. jejuni was evaluated
using chicken model system. As shown in Figure 2D, wild-type
C. jejuni 81–176 could colonize chicken eﬃciently on days 6
and 10 post-challenge with colonization level as high as 109
CFU per gram of feces. In contrast, the isogenic Cj0843c mutant
displayed signiﬁcantly reduced colonization in the intestine
(P < 0.05); the mutant was not detected in most of chickens.
Complementation with the plasmid did not rescue the impaired
colonization of the Cj0843c mutant, likely due to instability
of the plasmid in the complemented strain. To test this, an
in vitro plasmid stability assay was performed by subculturing
complemented strain every 2–3 days in fresh antibiotic-free
MH broth (1:400 dilution) for 10 days; by day 10, majority
of the cells (85%) were observed to lose the complemented
plasmid.
DISCUSSION
In this study, random transposon mutagenesis was used to
identify novel genes contributing to beta-lactam resistance in
C. jejuni, which led to the discovery of a putative LT Cj0843c
that plays an important role in the intrinsic and acquired
beta-lactam resistance in C. jejuni. Notably, the mutation of
Cj0843c signiﬁcantly reduced beta-lactamase activity and MIC
for ampicillin (Table 3 and Figure 1). The periplasmic Cj0843c
was prevalent and highly conserved in C. jejuni and other
ε-proteobacteria, such as C. coli and H. pylori (Supplementary
Figure S1 and Supplementary Table S1), indicating the critically
conserved role of Cj0843c in cell wall metabolism. Cj0843c
is also required for C. jejuni colonization in the intestine
(Figure 2D). Mutation of another cell wall metabolism-related
gene pgp1 was also observed to impair C. jejuni colonization
(Frirdich et al., 2012). However, at this stage, it is still
premature to speculate how Cj0843c is involved in colonization.
Mutation of Cj0843c may aﬀect C. jejuni physiology and
exert pleiotropic eﬀects that are related to C. jejuni in vivo
colonization.
The LT also have been observed to be involved in beta-
lactam resistance in other bacteria. For instance, single (MltB),
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FIGURE 2 | Characterization of Cj0843c. (A) Expression and purification of rCj0843c. Cj0843 fragment was cloned into pET-28b vector. Expression of rCj0843c
was induced in the presence of 0.5 mM IPTG. 0, 1 and 3 h, the cell lysates from pre-induction, 1 and 3 h induced cells; S, soluble fraction; IS, insoluble fraction; E,
elution fraction. (B) Cj0843c is localized in periplasm. The intracellular regulator CmeR was used as cytoplasm control. Per, periplasm; Sph, spheroplast; WT, wild
type. (C) Turbidimetric assay of rCj0843c. Chloroform-treated Cj0843c− mutant cells (crude cell walls) were mixed with rCj0843c or PBS control solution. The
decrease of absorbance at 450 nm was measured after 2.5 h incubation. Each bar represents the mean ± SD from three independent measurements. (D) Critical
role of Cj0843c in colonization of C. jejuni in chicken. The chickens in each group (10 birds) were inoculated with C. jejuni 81–176 (close circle), its isogenic Cj0843c
mutant (diamond), and complementation strain (triangle) at dose of 105 CFU/chicken. At days 6 and 10 post-challenge, five chickens from each group were killed
and cecal contents were collected for C. jejuni numeration. The detection limit is 102 CFU/gram fecal sample. Each horizontal line segment denotes the mean value
of log transformed CFU of different strains at the indicated days post-inoculation. The detection limit is 102 CFU/gram fecal sample.
double (MltA/MltB; Kraft et al., 1999) or sextuple (Slt70,
MltA, MltB, MltC, MltD, and EmtA; Korsak et al., 2005)
LT mutants in an E. coli MC1061 displayed signiﬁcantly
decreased beta-lactamase activity. Speciﬁc inhibition of the
LT Slt70 by bulgecin A suppressed the activity of beta-
lactamase AmpC in E. coli (Kraft et al., 1999). Notably,
not all PG-degrading enzymes are involved in beta-lactam
resistance. For instance, the deletion of two amidases (cleaving
the amide bond between N-acetylmuramic acid and L-Ala)
and three DD-endopeptidases (acting on the peptide cross-
links) had little eﬀect on beta-lactam resistance (Korsak et al.,
2005). In C. jejuni, inactivation of Pgp1, which is involved
in cleaving monomeric tripeptides to dipeptides (Frirdich
et al., 2012), did not aﬀect beta-lactamase activity and the
susceptibility of C. jejuni to ampicillin as shown in this
study.
The LT-mediated beta-lactam resistance identiﬁed
in this study indicates LT is a promising target for
combinational antimicrobial chemotherapy in C. jejuni,
even in ε-proteobacteria. Our genome survey suggested the
three-gene operon containing Cj0843c is conserved across
ε-proteobacteria. The LT-mediated beta-lactam resistance
mechanism might be also prevalent in ε-proteobacteria. For
example, the H. pylori homolog (Slt) shares high homology
to the Cj0843c (31% aa identity and 51% aa similarity).
Recently, Slt also has been found to contribute to amoxicillin
resistance in Helicobacter (Bonis et al., 2012). Bulgecin A,
the speciﬁc inhibitor of H. pylori Slt, could enhance the
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antimicrobial eﬀect of amoxicillin (Bonis et al., 2012). Given
amoxicillin is an important β-lactam component of the triple
therapy to eradicate H. pylori infection in human (Tepes et al.,
2012), LT inhibitor may serve as a good combination agent
(e.g., together with beta-lactam/beta-lactamase inhibitors) to
maximize the clinical eﬃcacy of beta-lactam antibiotics.
The decreased β-lactamase activity in LT mutants might
be correlated with altered metabolism of peptidoglycan
(Kraft et al., 1999). In Gram-negative bacteria, the LT-
degraded PG fragments, also called muropeptides, not only
serve as cell wall recycling materials during cell growth,
but also serve as a signal to turn on the production of
β-lactamase through an intracellular transcriptional regulator
(Jacobs et al., 1997; Boudreau et al., 2012; Zeng and Lin,
2013). Speciﬁcally, muropeptides was either transported
into cytoplasm through inner membrane transport AmpG
and bound by the regulator AmpR, or directly bound by
response regulators of the BlrAB-like two-component regulatory
system, to activate the expression of β-lactamase AmpC
(Boudreau et al., 2012; Zeng and Lin, 2013). Mutation of the
putative LT Cj0843c likely disrupt such intracellular signaling
pathway, therefore interfering the induced expression of beta-
lactamase and leading to signiﬁcantly reduced beta-lactamase
activity as well as ampicillin MIC observed in this study
(Figure 1). This speculation needs to be examined in future
studies.
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